摘要
目的探讨益气养荣组方治疗非小细胞肺癌化疗后骨髓抑制患者的临床疗效。方法选取2018年6月—2020年6月期间河北省沧州中西医结合医院中医康复科收治的非小细胞肺癌化疗后骨髓抑制患者120例作为研究对象,按随机数字表法分为对照组和试验组,每组各60例。对照组给予美洛培南治疗,试验组在对照组基础上联用益气养荣方汤剂,均治疗2周。观察比较两组患者骨髓抑制情况、不良反应发生情况,治疗前后外周血细胞计数、中医证候积分和生活质量评分。结果治疗后两组患者白细胞、粒细胞、血小板水平均较治疗前降低,血红蛋白水平均较治疗前升高,差异有统计学意义(P<0.05);且试验组外周血细胞计数明显优于对照组,差异有统计学意义(P<0.05)。治疗后两组患者咳嗽痰少、咳声低弱、神疲乏力、潮热盗汗、头晕眼花、面色少华积分均较治疗前降低,差异有统计学意义(P<0.05);且试验组中医证候积分明显低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者情绪功能、社会功能、躯体功能、角色功能、认知功能和总体健康评分均较治疗前升高,差异有统计学意义(P<0.05);且试验组生活质量评分明显高于对照组,差异有统计学意义(P<0.05)。治疗后试验组骨髓抑制分级中0级、Ⅱ级、Ⅲ级及Ⅳ级均低于对照组,差异有统计学意义(P<0.05);两组患者骨髓抑制分级中0级比较,差异无统计学意义(P>0.05)。治疗期间,两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论美洛培南联合益气养荣组方治疗非小细胞肺癌化疗后骨髓抑制患者疗效较好,且安全性高。
Objective To explore the clinical efficacy of Yiqi Yangrong Prescription in treating myelosuppression in patients with non-small cell lung cancer(NSCLC)after chemotherapy.Methods A total of 120 NSCLC patients with chemotherapy-induced myelosuppression,treated at the Traditional Chinese Medicine Rehabilitation Department of Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine from June 2018 to June 2020,were selected and randomly divided into a control group and an experimental group according to a random number table,with 60 patients in each group.The control group was treated with meropenem,while the experimental group received Yiqi Yangrong Prescription in addition to meropenem.Both groups were treated for 2 weeks.The myelosuppression,incidence of adverse reactions,peripheral blood cell count,traditional Chinese medicine(TCM)symptom scores,and quality of life scores were compared between the two groups before and after treatment.Results After treatment,white blood cell,granulocyte,and platelet levels decreased,while hemoglobin levels increased significantly in both groups compared to those before treatment(P<0.05).The peripheral blood cell counts in the experimental group were significantly better than those in the control group(P<0.05).TCM symptom scores for cough with little sputum,weak cough,fatigue,tidal fever and night sweats,dizziness,and pale complexion were significantly lower in both groups after treatment(P<0.05),with the experimental group showing significantly lower scores than the control group(P<0.05).Quality of life scores for emotional,social,physical,role,and cognitive functions,as well as overall health,significantly increased in both groups after treatment(P<0.05),with the experimental group scoring significantly higher than the control group(P<0.05).The myelosuppression grades of 0,II,III,and IV in the experimental group were significantly lower than those in the control group(P<0.05),although there was no significant difference in grade 0 between the two groups(
作者
王洪亮
王振强
张庆江
李小江
赵芳
赵阳
董雪珊
陈晶晶
周雍明
WANG Hong-liang;WANG Zhen-qiang;ZHANG Qing-jiang;LI Xiao-jiang;ZHAO Fang;ZHAO Yang;DONGXue-shan;CHEN Jing-jing;ZHOU Yong-ming(Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine,Hebei University of Chinese Medicine,Cangzhou Hebei 061000;First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300073;Guang′anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053)
出处
《世界中西医结合杂志》
2024年第6期1227-1231,共5页
World Journal of Integrated Traditional and Western Medicine
基金
河北省中医药管理局课题(2017297)。
关键词
小细胞肺癌
化疗
骨髓抑制
益气养荣组方
Small Cell Lung Cancer
Chemotherapy
Myelosuppression
Yiqi Yangrong Prescription
